Related Experiment Videos

[Experience in coenzyme Q10 application in complex therapy of coronary heart disease with dyslipidemia]

O L Belaia, V I Kalmykova, L A Ivanova

    Klinicheskaia Meditsina
    |July 11, 2006
    PubMed

    Insights

    Adding ubiquinone Q10 and alpha-tocopherol (Cudesan) to simvastatin (Vasilip) therapy improved antioxidant status and reduced lipid peroxidation in coronary heart disease patients. This combination therapy offers potential benefits beyond statin monotherapy for managing dyslipidemia.

    Area of Science:

    • Cardiology
    • Biochemistry
    • Pharmacology

    Background:

    • Coronary heart disease (CHD) and dyslipidemia are significant cardiovascular risk factors.
    • Conventional statin therapy, like simvastatin (Vasilip), effectively lowers LDL cholesterol but can increase oxidative stress.
    • Antioxidants such as ubiquinone Q10 and alpha-tocopherol may mitigate statin-induced oxidative stress.

    Purpose of the Study:

    • To evaluate the combined effects of simvastatin (Vasilip) and a Cudesan supplement (ubiquinone Q10 and alpha-tocopherol) on lipid profiles, lipid peroxidation, and antioxidant status in patients with CHD and dyslipidemia.
    • To compare the efficacy of simvastatin monotherapy versus combination therapy with Cudesan.

    Main Methods:

    • A study involving 43 patients with functional class II-III CHD and dyslipidemia receiving conventional therapy.
    • Patients were divided into two groups: Group I received simvastatin (Vasilip) 20 mg/day; Group II received simvastatin (Vasilip) 20 mg/day plus Cudesan (1 ml/day, containing 30 mg ubiquinone Q10 and 4.5 mg alpha-tocopherol).
    • Blood samples were analyzed for lipid levels, lipid peroxidation products, and antioxidant status markers (ceruloplasmin, transferrin) after one month.

    Main Results:

    • Simvastatin monotherapy achieved target LDL cholesterol levels in 62-65% of patients but significantly increased lipid peroxidation (25-29%) and decreased antioxidant status (6% reduction in ceruloplasmin and CP:TF ratio).
    • Combination therapy with Cudesan and simvastatin significantly decreased lipid peroxidation (30-29%) and increased serum ceruloplasmin (25.7%) and the CP:TF ratio (12.5%).
    • Both groups showed effectiveness in lowering LDL cholesterol, but only the combination group demonstrated improved antioxidant markers and reduced oxidative stress.

    Conclusions:

    • Simvastatin monotherapy, while effective for LDL reduction, may exacerbate oxidative stress in CHD patients.
    • The addition of Cudesan (ubiquinone Q10 and alpha-tocopherol) to simvastatin therapy significantly improves antioxidant status and reduces lipid peroxidation.
    • Combination therapy represents a promising strategy for comprehensive management of dyslipidemia and oxidative stress in coronary heart disease.

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    Rheumatic Heart Disease III: Medical Management01:21

    Rheumatic Heart Disease III: Medical Management

    Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
    Coronary Artery Disease III: Clinical Manifestations01:30

    Coronary Artery Disease III: Clinical Manifestations

    Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Coronary Artery Disease I: Introduction01:30

    Coronary Artery Disease I: Introduction

    Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...